# A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants

> **NCT07549750** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Helixon Biotechnology (Suzhou) Co., Ltd** · enrollment: 28 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** HXN5003
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07549750
- **Lead sponsor:** Helixon Biotechnology (Suzhou) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-27
- **Primary completion:** 2027-03-18
- **Final completion:** 2027-04-16
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07549750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07549750, "A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07549750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*